
- | F2G
Valley Fever: What are the Signs and Symptoms
“Symptoms depend on the stage of disease and also which organs are affected,” said Dr. Emma Harvey, Global Head of Medical Affairs at the clinical-stage biopharmaceutical company F2G. “It starts as a respiratory disease and can be indistinguishable on symptoms from viral or bacterial pneumonia.”

- | Elixirgen Therapeutics
Using Self-Replicating RNA Technology to Treat Telomere Biology Disorders with Akihiro Ko Elixirgen Therapeutics
Akihiro Ko is the CEO and Co-Founder of Elixirgen Therapeutics, which was founded with the mission of treating patients using RNA technology. Their c-srRNA, controllable self-replicating RNA, technology is being applied to telomere biology disorders where patients have inherited short telomeres and a failure to develop bone marrow. Elixirgen is looking to restore the ability to create blood cells in patients suffering from this rare disease.

- | Canary Medical
Lessons from Serial CEOs in the Life Sciences
My biggest challenge was financing Canary. I think the concept behind Canary is timely, highly medically relevant, and an obvious next step in the evolution of medical devices—life-saving

- | F2G
4 issues infectious disease experts are focused on as fewer enter their profession
John Rex, MD, chief medical officer at drug discovery company F2G, told Becker’s he also feels the solution is two-part: legislative and research-driven.

- | CytoReason
Sanofi and CytoReason Target IBD in Expanded Collaboration (Updated)
If data is the new oil, CytoReason is one of its barons. Combining all available information about a disease – literature, data sets, all data types – the company builds computational disease models utilized by its pharma partners to help them determine which drug avenues to pursue next.

- | Elicio Therapeutics
Cancer vaccine developer jumps to Nasdaq via reverse merger
Elicio is merging with Angion Biomedica, a Uniondale, NY-based biotech that began searching for strategic alternatives last July after Phase II setbacks forced it to shutter all R&D work.

- | PepGen
Reporter’s Notebook: Opening Day at the J.P. Morgan Healthcare Conference
In 2021, PepGen raised $113 million to challenge Sarepta in DMD and build its neuromuscular and neurologic pipeline.

- | Immunome
Betting on cell memory, AbbVie pays Immunome $30M upfront to further antibody research
AbbVie has tapped Immunome’s discovery platform in a heavily backended partnership and option agreement in a bid to discover 10 antibody-target pairs from three as-yet-unnamed tumor types.